Yoichi Nakamura

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

Takeshi Kitazaki, Mikio Oka, Yoichi Nakamura et al. · Lung Cancer · 2005 · 179 citations

Medicine, Oncology, Pharmacology +13

Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

Yoichi Nakamura, Mikio Oka, Hiroshi Soda et al. · Cancer Research · 2005 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic

Ken Shiozawa, Mikio Oka, Hiroshi Soda et al. · International Journal of Cancer · 2003 · 121 citations

Medicine, Oncology, Pharmacology +16

Effects of exercise frequency on functional fitness in older adult women

Yoichi Nakamura, Kiyoji Tanaka, Noriko Yabushita et al. · Archives of Gerontology and Geriatrics · 2006 · 113 citations

Education, Kinesiology, Physiology +14

Expression and functional analyses of breast cancer resistance protein in lung cancer.

Shigeru Kawabata, Mikio Oka, Hiroshi Soda et al. · PubMed · 2003 · 94 citations

Medicine, Oncology, Pharmacology +17